The application for conducting Phase I clinical trials of HZ-V055 capsules, a pan-RAS inhibitor developed by Hezheng Medicine, for the treatment of late-stage solid tumors with RAS mutations has been accepted.

On May 26, Hangzhou Hanzheng Pharmaceutical Co., Ltd. announced that its developed first-in-class innovative drug pan-RAS inhibitor HZ-V055 capsules have applied for Phase I clinical trials for the treatment of advanced solid tumors with RAS mutations, and have been accepted by the Drug Evaluation Center. This application is the company's first registration application submitted in eCTD format since the National Medical Products Administration fully implemented the electronic Common Technical Document submission.